Nasal Alzheimer’s Drops Spark U.S. Rush

Patient arm with IV line in a hospital chair — Photo: goodbishop / Shutterstock

Ninety miles from Florida, American families are flying to Havana and lining up for a nasal-drop Alzheimer’s treatment they cannot get at home.

At a Glance

U.S. citizens are traveling to Cuba to seek NeuralCIM, a nasal form of NeuroEPO.
Cuba launched large Phase III and IV studies to expand access across the country.
Peer-reviewed Cuban trials report cognitive gains and strong short-term safety.
Cuba’s medical tourism infrastructure eases foreign patient entry to care.

Cuba Opens The Door As Trials Scale Nationwide

Cuban health authorities began a Phase III clinical trial of NeuralCIM, the commercial name for NeuroEPO, on February 27, 2024. The Center for Molecular Immunology leads the effort, with sites in Havana and in provinces around the country. The Cuban News Agency reported the country also organized Phase IV work with the public health ministry, signaling broader, real-world use alongside the controlled trial network. This scale-up created a clear path for patients to be screened and enrolled.

Havana’s municipal government announced classification consultations at eight health centers to sort potential trial candidates. That process aimed to identify people with mild to moderate Alzheimer’s who might benefit and meet entry rules. This is how family members found an entry point: show up for screening, get the diagnosis confirmed, and join a treatment track. The nasal delivery, given on set days each week, made it easier for outpatient management across clinics.

What NeuralCIM Is And What The Data Show

NeuralCIM is a reformulated erythropoietin designed for the brain, without red-blood-cell effects. Patients take it as nasal drops that aim to reach the central nervous system. A Cuban randomized, double-blind Phase 2–3 trial of NeuroEPO plus standard drugs reported better cognitive scores at 48 weeks than placebo and a very good safety profile. A subsequent analysis described benefits across common measures like cognition and daily function, again aligning with earlier signals.

Review articles summarize a small but focused human evidence base. They highlight significant cognitive improvement signals in randomized settings and call for larger multicenter trials to confirm effect size and durability. That is the normal arc in Alzheimer’s research: show benefit in a controlled setting, then scale to broader populations and longer follow-up. Cuba’s nationwide expansion seeks exactly that next step while giving patients access now.

Why Americans Are Flying South For Care

Families want options faster than the slow United States approval path can deliver, especially when a loved one declines month by month. Cuba’s health system has long welcomed medical travelers and built services that package lodging, logistics, and clinical care. When word spread that Cuban clinics screened candidates for NeuralCIM and had open slots, U.S. citizens began to book flights and appointments. The practical draw is simple: evaluation, a place in a program, and a clear schedule of care.

Voices in U.S. media have framed the gap as access blocked by policy and politics rather than science alone, pointing to an approved path in Cuba versus a closed door at home. Families should have the freedom to pursue lawful care that they judge best, especially for a disease that robs memory and independence. The market is already speaking: people will travel, pay cash, and organize support if a credible pathway exists.

What Families Should Weigh Before They Go

Patients and caregivers should ask three core questions. First, does the person fit the mild-to-moderate stage that Cuban trials studied? Second, can the family support regular dosing and follow-up that can extend many months? Third, will current medications at home align with the Cuban protocol? The published trial used NeuroEPO plus standard Alzheimer’s drugs and reported better outcomes than placebo on cognition tests such as the Alzheimer’s Disease Assessment Scale. Bring records and a medication list to speed screening.

Travel logistics also matter. Cuba’s clinics can coordinate evaluation, but families must plan flights, housing, and time away. Medical tourism programs can help with bundles and local transport. Keep expectations in check. The peer-reviewed signals show promise and safety, not a cure. Yet for many families, slowing decline or improving daily thinking is worth the trip. That is why the line in Havana keeps growing, one caregiver’s bet at a time.